$EVOK
Evoke Pharma Inc

2014 Q2 Form 10-Q Financial Statement

#000119312514197023 Filed on May 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $620.0K $1.070M $220.0K
YoY Change 785.71% 386.36% 4.76%
% of Gross Profit
Research & Development $2.875M $1.852M $111.0K
YoY Change 2097.22% 1568.86% -62.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.492M $2.923M $332.0K
YoY Change 1616.55% 780.22% 11.69%
Operating Profit -$3.492M -$2.923M -$332.0K
YoY Change 1616.55% 780.22%
Interest Expense -$60.00K $36.94K -$40.00K
YoY Change 50.0% -192.36%
% of Operating Profit
Other Income/Expense, Net -$55.18K -$32.89K -$162.0K
YoY Change 51.38% -79.69%
Pretax Income -$3.550M -$2.960M -$490.0K
YoY Change 1379.17% 504.08% -2.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.547M -$2.955M -$494.0K
YoY Change 1378.73% 498.29% -1.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$588.7K -$493.3K -$433.6K
COMMON SHARES
Basic Shares Outstanding 6.100M shares 6.100M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.05M $21.84M $1.670M
YoY Change 1428.57% 1207.78%
Cash & Equivalents $16.05M $21.84M $1.670M
Short-Term Investments
Other Short-Term Assets $890.0K $180.0K $0.00
YoY Change
Inventory
Prepaid Expenses $888.9K $176.2K
Receivables
Other Receivables
Total Short-Term Assets $16.93M $22.01M $1.670M
YoY Change 1512.83% 1218.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $88.46K $555.5K $10.00K
YoY Change -88.05% 5455.05%
Total Long-Term Assets $88.46K $555.5K $10.00K
YoY Change -88.05% 5455.05%
TOTAL ASSETS
Total Short-Term Assets $16.93M $22.01M $1.670M
Total Long-Term Assets $88.46K $555.5K $10.00K
Total Assets $17.02M $22.57M $1.680M
YoY Change 851.01% 1243.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.300M $1.120M $270.0K
YoY Change 116.67% 314.81%
Accrued Expenses $540.0K $390.0K $170.0K
YoY Change 184.21% 129.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.443M
YoY Change -100.0%
Total Short-Term Liabilities $1.837M $2.944M $670.0K
YoY Change 7.43% 339.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.157M $2.940M
YoY Change -100.0% -60.66%
Other Long-Term Liabilities $20.00K $20.00K
YoY Change
Total Long-Term Liabilities $20.00K $1.157M $2.940M
YoY Change -99.11% -60.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.837M $2.944M $670.0K
Total Long-Term Liabilities $20.00K $1.157M $2.940M
Total Liabilities $1.854M $4.116M $3.610M
YoY Change -53.07% 14.02%
SHAREHOLDERS EQUITY
Retained Earnings -$29.19M
YoY Change
Common Stock $610.00 $610.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.17M $18.45M -$1.930M
YoY Change
Total Liabilities & Shareholders Equity $17.02M $22.57M $1.680M
YoY Change 851.01% 1243.29%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$3.547M -$2.955M -$494.0K
YoY Change 1378.73% 498.29% -1.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.070M -$2.001M -$446.5K
YoY Change 613.95% 348.07% -0.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.720M -360.6K 2.000M
YoY Change 1331.58% -118.03%
NET CHANGE
Cash From Operating Activities -3.070M -2.001M -446.5K
Cash From Investing Activities
Cash From Financing Activities -2.720M -360.6K 2.000M
Net Change In Cash -5.790M -2.361M 1.554M
YoY Change 833.87% -251.99% -445.22%
FREE CASH FLOW
Cash From Operating Activities -$3.070M -$2.001M -$446.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6099547 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6099547 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1156701
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44097429
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2943944
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
385499
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
18451087
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1115853
CY2014Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
15518
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
610
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1669518
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6099547 shares
us-gaap Interest Expense Other
InterestExpenseOther
402771
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22567250
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6096752 shares
CY2014Q1 us-gaap Liabilities
Liabilities
4116163
CY2014Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1442592
CY2014Q1 us-gaap Assets Current
AssetsCurrent
22011745
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54264
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
176247
CY2014Q1 us-gaap Assets
Assets
22567250
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21835498
CY2014Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
25646952
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2903000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
284915
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6830
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
610
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6096752 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1511461
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43874119
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2284906
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
557399
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21183261
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24986458
CY2013Q4 us-gaap Liabilities
Liabilities
3803197
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1442592
CY2013Q4 us-gaap Assets Current
AssetsCurrent
24430953
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234262
CY2013Q4 us-gaap Assets
Assets
24986458
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
22691468
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
108486 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24024853
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-15518
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
555505
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2860576
us-gaap Interest Income Other
InterestIncomeOther
225155
us-gaap Revenue From Grants
RevenueFromGrants
244000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25470485
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
176247
us-gaap Interest Paid
InterestPaid
261246
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-176467
us-gaap Net Income Loss
NetIncomeLoss
-25646952
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
292538
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
17744041
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1501352
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6019860
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45860351
evok Change In Fair Value Of Purchase Right Liability
ChangeInFairValueOfPurchaseRightLiability
188587
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
5500000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
18225166
us-gaap Share Based Compensation
ShareBasedCompensation
458987
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21835498
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25125528
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18800625
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101358
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Other Noncash Expense
OtherNoncashExpense
135143
us-gaap Operating Expenses
OperatingExpenses
25470485
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
250000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1133375 shares
CY2013Q1 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
49000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-446495
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2584252 shares
CY2013Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
109375 shares
CY2013Q1 us-gaap Interest Income Other
InterestIncomeOther
1353
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-332030
CY2013Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10500
CY2013Q1 us-gaap Interest Paid
InterestPaid
25750
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-161962
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-493992
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-74944
CY2013Q1 us-gaap Interest Expense Other
InterestExpenseOther
39315
CY2013Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
124000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
221049
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000000
CY2013Q1 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
2000000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3126
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1553505
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
110981
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
5815
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
332030
CY2014Q1 dei Trading Symbol
TradingSymbol
EVOK
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6002936 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2000617
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M23D
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
732090 shares
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2014Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
94375 shares
CY2014Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8688
CY2014Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
360576
CY2014Q1 us-gaap Interest Income Other
InterestIncomeOther
4055
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2922595
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-58015
CY2014Q1 us-gaap Interest Paid
InterestPaid
32495
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32889
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2955484
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
659038
CY2014Q1 us-gaap Interest Expense Other
InterestExpenseOther
36944
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1070479
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-360576
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
223310
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2361193
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1852116
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
5816
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2922595

Files In Submission

Name View Source Status
0001193125-14-197023-index-headers.html Edgar Link pending
0001193125-14-197023-index.html Edgar Link pending
0001193125-14-197023.txt Edgar Link pending
0001193125-14-197023-xbrl.zip Edgar Link pending
d690289d10q.htm Edgar Link pending
d690289dex311.htm Edgar Link pending
d690289dex312.htm Edgar Link pending
d690289dex321.htm Edgar Link pending
d690289dex322.htm Edgar Link pending
evok-20140331.xml Edgar Link completed
evok-20140331.xsd Edgar Link pending
evok-20140331_cal.xml Edgar Link unprocessable
evok-20140331_def.xml Edgar Link unprocessable
evok-20140331_lab.xml Edgar Link unprocessable
evok-20140331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending